Table 1 The relationship between biomarker levels and whether a pathologic complete response (pCR) was achieved, adjusted for estrogen receptor status (all arms pooled)
Biomarker* | Patients achieving a pCR in the ‘high’ or ‘yes’ subgroup, n/N (%) | Patients achieving a pCR in the ‘low’ or ‘no’ subgroup, n/N (%) | P value (chi-squared test) |
|---|---|---|---|
HER2 membrane | 115/159 (72.3) | 24/66 (36.4) | 0.00002 |
HER3 membrane | 32/58 (55.2) | 38/54 (70.4) | 0.32864 |
IGF-1R membrane | 27/57 (47.4) | 44/56 (78.6) | 0.05313 |
EGFR membrane | 21/36 (58.3) | 48/73 (65.8) | 0.01037 |
PTEN cytoplasmic | 59/92 (64.1) | 11/21 (52.4) | 0.04968 |
PTEN nuclear | 39/60 (65.0) | 31/53 (58.5) | 0.22086 |
EGFR mRNA | 65/98 (66.3) | 60/98 (61.2) | 0.65169 |
HER2 mRNA | 78/106 (73.6) | 53/104 (51.0) | 0.00060 |
HER3 mRNA | 60/105 (57.1) | 71/105 (67.6) | 0.89283 |
Amphiregulin mRNA | 55/95 (57.9) | 66/95 (69.5) | 0.42068 |
TOP2A | 35/62 (56.5) | 83/130 (63.9) | 0.57728 |
c-Myc | 40/61 (65.6) | 66/106 (62.3) | 0.52483 |
Amphiregulin | 68/102 (66.7) | 62/101 (61.4) | 0.29743 |
EGF | 65/102 (63.7) | 65/101 (64.4) | 0.83132 |
sHER2 | 68/102 (66.7) | 62/101 (61.4) | 0.89167 |
TGFα | 60/102 (58.8) | 70/101 (69.3) | 0.16475 |
PIK3CA mutation | 19/39 (48.7) | 81/126 (64.3) | 0.17160 |